Emily K. Yeung

Emily K. Yeung

Auto-generated profile, based on publicly available information

Emily K. Yeung

The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
EYEmily Yeung
Emily Yeung
ABAk Bello
Ak Bello
ALAdeera Levin
Adeera Levin
MLMeaghan Lunney
Meaghan Lunney
MOMohamed A Osman
Mohamed A Osman
DJDavid Johnson
David Johnson
Objectives The Global Kidney Health Atlas (GKHA) is a multinational, cross-sectional survey designed to assess the current capacity for kidney care across all world regions. The 2017 GKHA involved 125 countries and identified significant gaps in oversight, funding and infrastructure to support care for patients with kidney disease, especially in lower-middle-income countries. Here, we report results from the survey for the second iteration of the GKHA conducted in 2018, which included specific questions about health financing and oversight of end-stage kidney disease (ESKD) care worldwide. Setting A cross-sectional global survey. Participants Key stakeholders from 182 countries were invited to participate. Of those, stakeholders from 160 countries participated and were included. Primary outcomes Primary outcomes included cost of kidney replacement therapy (KRT), funding for dialysis and transplantation, funding for conservative kidney management, extent of universal health coverage, out-of-pocket costs for KRT, within-country variability in ESKD care delivery and oversight systems for ESKD care. Outcomes were determined from a combination of desk research and input from key stakeholders in participating countries. Results 160 countries (covering 98% of the world’s population) responded to the survey. Economic factors were identified as the top barrier to optimal ESKD care in 99 countries (64%). Full public funding for KRT was more common than for conservative kidney management (43% vs 28%). Among countries that provided at least some public coverage for KRT, 75% covered all citizens. Within-country variation in ESKD care delivery was reported in 40% of countries. Oversight of ESKD care was present in all high-income countries but was absent in 13% of low-income, 3% of lower-middle-income, and 10% of upper-middle-income countries. Conclusion Significant gaps and variability exist in the public funding and oversight of ESKD care in many countries, particularly for those in low-income and lower-middle-income countries.

30 November 2022 in Nephrology
Verified
Journal Article
Closed access
EYEmily K. Yeung
Emily K. Yeung
LBLeanne Brown
Leanne Brown
LKLukas Kairaitis
Lukas Kairaitis
RKRathika Krishnasamy
Rathika Krishnasamy
CLCasey Light
Casey Light
MRMatthew A. Roberts
Matthew A. Roberts

15 May 2026 in JACC: Heart Failure
Verified
Journal Article
Closed access
EYEmily K. Yeung
Emily K. Yeung
LHLauren Heath
Lauren Heath
PMPatrick B. Mark
Patrick B. Mark
MVMuthiah Vaduganathan
Muthiah Vaduganathan
SKSradha S. Kotwal
Sradha S. Kotwal
BNBrendon L. Neuen
Brendon L. Neuen

23 June 2026 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
EYEmily K Yeung
Emily K Yeung
JRJanani Rangaswami
Janani Rangaswami
KTKatherine R. Tuttle
Katherine R. Tuttle
MGMorgan E. Grams
Morgan E. Grams
NTNavdeep Tangri
Navdeep Tangri
BNBrendon L Neuen
Brendon L Neuen
Therapeutic options for chronic kidney disease (CKD) have expanded substantially in recent years, creating new opportunities to reduce residual kidney and cardiovascular risk through combination therapy. Evidence from large, randomized trials and meta-analyses demonstrates that sodium-glucose co-transporter 2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and glucagon-like peptide-1 (GLP-1) receptor agonists provide independent and additive benefits, with emerging data showing that select combinations may also improve safety. A risk-based approach, anchored in albuminuria and supported by validated risk equations, can guide treatment intensity, support more timely initiation of multidrug regimens, and improve health system efficiency. Addressing implementation barriers, advancing single-pill combinations, and leveraging adaptive and combination therapy trials will be essential to translate these therapeutic advances into improved long-term outcomes for people with CKD.

Verified
Journal Article
Open access
PDF file
SNShiori Nakagawa
Shiori Nakagawa
EYEmily K. Yeung
Emily K. Yeung
AHAlberta Hoi
Alberta Hoi
EMEric Morand
Eric Morand
JKJoanna Kent
Joanna Kent
RKRangi Kandane-Rathnayake
Rangi Kandane-Rathnayake
Reliable clinical markers for predicting sustained renal remission remain poorly understood in patients with lupus nephritis (LN). We investigated whether achieving complete renal remission (CRR) within 6 months of induction therapy, compared to within 12 months, was associated with a higher likelihood of attaining CRR at 24 months. We conducted a retrospective observational study of biopsy-proven patients with class III or IV ± V LN treated at a lupus clinic in Australia. CRR was defined as a urine protein: creatinine ratio (UPCR) of 10% from baseline. CRR responders at 6, 12, and 24 months were determined. Associations between 6- and 12-month CRR status and 24-month CRR were examined using logistic regression. In total, 60 patients were included; 49 (82%) were female, with a median age of 27 years (IQR: 19, 39) at LN diagnosis. CRR was attained at 6, 12, and 24 months by 23 (40%), 26 (47%), and 24 (44%) of patients, respectively. Both 6- and 12-month CRR attainment were significantly associated with an increased likelihood of CRR achievement at 24 months (adjusted odds ratios 11.23 (95% CI 2.53, 49.88) and 11.39 (95% CI 2.41, 53.80), respectively). Achieving CRR at 6 and 12 months was a strong independent predictor for attaining subsequent renal remission.